Johnson & Johnson (NYSE:JNJ) Stock Price Up 2.1% - Time to Buy?

Key Points

• Johnson & Johnson's stock increased by 2.1%, closing at $185.40 after trading as high as $185.99, with a significant trading volume of over 11 million shares.
• Several research firms have upgraded their ratings, with Guggenheim raising the price target to $206, indicating a positive outlook for the stock.
• The company reported earnings of $2.77 per share, surpassing estimates and showing a year-over-year revenue increase of 5.8%, with a quarterly dividend payout of $1.30.

Shares of Johnson & Johnson (NYSE:JNJ - Get Free Report) shot up 2.1% on Tuesday . The stock traded as high as $185.99 and last traded at $185.40. 11,393,198 shares changed hands during mid-day trading, an increase of 27% from the average session volume of 8,940,017 shares. The stock had previously closed at $181.62.

Analyst Ratings Changes

Several research firms have recently weighed in on JNJ. Guggenheim raised Johnson & Johnson from a "neutral" rating to a "buy" rating and increased their price objective for the company from $167.00 to $206.00 in a report on Tuesday, September 23rd. Bank of America increased their price objective on Johnson & Johnson from $161.00 to $175.00 and gave the company a "neutral" rating in a report on Thursday, July 17th. Morgan Stanley increased their price objective on Johnson & Johnson from $171.00 to $176.00 and gave the company an "equal weight" rating in a report on Thursday, July 17th. JPMorgan Chase & Co. increased their price objective on Johnson & Johnson from $185.00 to $200.00 and gave the company a "neutral" rating in a report on Tuesday, September 16th. Finally, Royal Bank Of Canada increased their price objective on Johnson & Johnson from $181.00 to $185.00 and gave the company an "outperform" rating in a report on Thursday, July 17th. Two investment analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and nine have given a Hold rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $181.40.

Johnson & Johnson Trading Up 2.1%

The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50. The company has a fifty day moving average of $174.76 and a two-hundred day moving average of $162.18. The stock has a market capitalization of $446.51 billion, a price-to-earnings ratio of 19.83, a P/E/G ratio of 2.29 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, topping the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The firm had revenue of $23.74 billion during the quarter, compared to the consensus estimate of $22.85 billion. During the same period last year, the company earned $2.82 earnings per share. The company's revenue for the quarter was up 5.8% on a year-over-year basis. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. On average, research analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th were given a $1.30 dividend. The ex-dividend date was Tuesday, August 26th. This represents a $5.20 annualized dividend and a yield of 2.8%. Johnson & Johnson's dividend payout ratio is presently 55.61%.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the transaction, the executive vice president owned 178,013 shares in the company, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 0.16% of the company's stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of JNJ. W.H. Cornerstone Investments Inc. increased its position in shares of Johnson & Johnson by 0.7% in the second quarter. W.H. Cornerstone Investments Inc. now owns 7,896 shares of the company's stock valued at $1,206,000 after buying an additional 58 shares in the last quarter. YANKCOM Partnership increased its position in shares of Johnson & Johnson by 0.8% in the second quarter. YANKCOM Partnership now owns 7,042 shares of the company's stock valued at $1,076,000 after buying an additional 58 shares in the last quarter. Greenup Street Wealth Management LLC increased its position in shares of Johnson & Johnson by 3.1% in the second quarter. Greenup Street Wealth Management LLC now owns 2,021 shares of the company's stock valued at $309,000 after buying an additional 60 shares in the last quarter. Ellis Investment Partners LLC increased its position in shares of Johnson & Johnson by 0.7% in the second quarter. Ellis Investment Partners LLC now owns 8,559 shares of the company's stock valued at $1,307,000 after buying an additional 62 shares in the last quarter. Finally, Cypress Wealth Services LLC increased its position in shares of Johnson & Johnson by 0.9% in the second quarter. Cypress Wealth Services LLC now owns 6,634 shares of the company's stock valued at $1,013,000 after buying an additional 62 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company's stock.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.